Pharmarise Holdings Corporation (TYO:2796)
Japan
· Delayed Price · Currency is JPY 520.00
+1.00 (0.19%)
Apr 28, 2026, 3:30 PM JST
Pharmarise Holdings Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 | May '21 May 31, 2021 | 2020 - 2016 |
| Revenue | 67,485 | 63,508 | 54,466 | 52,030 | 51,608 | 52,324 | Upgrade
|
| Revenue Growth (YoY) | 11.85% | 16.60% | 4.68% | 0.82% | -1.37% | 2.54% | Upgrade
|
| Cost of Revenue | 58,152 | 54,542 | 46,017 | 43,896 | 43,491 | 44,256 | Upgrade
|
| Gross Profit | 9,333 | 8,966 | 8,449 | 8,134 | 8,117 | 8,068 | Upgrade
|
| Selling, General & Admin | 4,731 | 4,860 | 4,371 | 3,728 | 3,525 | 3,659 | Upgrade
|
| Amortization of Goodwill & Intangibles | 763 | 763 | 557 | 635 | 700 | 738 | Upgrade
|
| Other Operating Expenses | 3,048 | 3,048 | 2,605 | 2,332 | 2,371 | 2,417 | Upgrade
|
| Operating Expenses | 8,542 | 8,671 | 7,533 | 6,695 | 6,596 | 6,821 | Upgrade
|
| Operating Income | 791 | 295 | 916 | 1,439 | 1,521 | 1,247 | Upgrade
|
| Interest Expense | -251 | -178 | -66 | -55 | -65 | -75 | Upgrade
|
| Interest & Investment Income | 13 | 10 | 1 | 2 | 2 | 2 | Upgrade
|
| Other Non Operating Income (Expenses) | 3 | -10 | -19 | 44 | 58 | 54 | Upgrade
|
| EBT Excluding Unusual Items | 556 | 117 | 832 | 1,430 | 1,516 | 1,228 | Upgrade
|
| Gain (Loss) on Sale of Investments | 4 | 7 | 19 | 30 | - | -4 | Upgrade
|
| Gain (Loss) on Sale of Assets | 37 | 20 | -1 | -4 | 2 | 61 | Upgrade
|
| Asset Writedown | -238 | -258 | -296 | -393 | -218 | -51 | Upgrade
|
| Other Unusual Items | 151 | 124 | -411 | -14 | 21 | -32 | Upgrade
|
| Pretax Income | 474 | 10 | 143 | 1,049 | 1,321 | 1,202 | Upgrade
|
| Income Tax Expense | 589 | 390 | 485 | 702 | 864 | 782 | Upgrade
|
| Earnings From Continuing Operations | -115 | -380 | -342 | 347 | 457 | 420 | Upgrade
|
| Minority Interest in Earnings | 7 | 13 | -9 | -14 | -10 | 6 | Upgrade
|
| Net Income | -108 | -367 | -351 | 333 | 447 | 426 | Upgrade
|
| Net Income to Common | -108 | -367 | -351 | 333 | 447 | 426 | Upgrade
|
| Net Income Growth | - | - | - | -25.50% | 4.93% | -26.17% | Upgrade
|
| Shares Outstanding (Basic) | 12 | 11 | 11 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 11 | 11 | 12 | 12 | 12 | Upgrade
|
| Shares Change (YoY) | 1.58% | 7.58% | -15.61% | 0.59% | 0.20% | -1.03% | Upgrade
|
| EPS (Basic) | -9.46 | -32.42 | -33.35 | 35.42 | 47.90 | 45.78 | Upgrade
|
| EPS (Diluted) | -9.46 | -32.42 | -33.35 | 26.86 | 36.22 | 34.59 | Upgrade
|
| EPS Growth | - | - | - | -25.83% | 4.70% | -25.31% | Upgrade
|
| Free Cash Flow | - | 674 | 2,242 | 2,140 | 334 | 1,437 | Upgrade
|
| Free Cash Flow Per Share | - | 59.53 | 213.04 | 171.61 | 26.94 | 116.15 | Upgrade
|
| Dividend Per Share | 14.000 | 14.000 | 14.000 | 14.000 | 14.000 | 14.000 | Upgrade
|
| Gross Margin | - | 14.12% | 15.51% | 15.63% | 15.73% | 15.42% | Upgrade
|
| Operating Margin | 1.17% | 0.46% | 1.68% | 2.77% | 2.95% | 2.38% | Upgrade
|
| Profit Margin | -0.16% | -0.58% | -0.64% | 0.64% | 0.87% | 0.81% | Upgrade
|
| Free Cash Flow Margin | - | 1.06% | 4.12% | 4.11% | 0.65% | 2.75% | Upgrade
|
| EBITDA | 2,526 | 1,788 | 2,086 | 2,663 | 2,829 | 2,591 | Upgrade
|
| EBITDA Margin | - | 2.81% | 3.83% | 5.12% | 5.48% | 4.95% | Upgrade
|
| D&A For EBITDA | 1,735 | 1,493 | 1,170 | 1,224 | 1,308 | 1,344 | Upgrade
|
| EBIT | 791 | 295 | 916 | 1,439 | 1,521 | 1,247 | Upgrade
|
| EBIT Margin | - | 0.46% | 1.68% | 2.77% | 2.95% | 2.38% | Upgrade
|
| Effective Tax Rate | - | 3900.00% | 339.16% | 66.92% | 65.41% | 65.06% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.